Seelos Therapeutics Inc (SEEL)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Seelos Therapeutics Inc chart...

About the Company

seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a

CEO

Raj Mehra

Exchange

NASDAQ

Website

https://seelostherapeutics.com/

$32M

Total Revenue

20

Employees

$6M

Market Capitalization

-0.26

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SEEL News

Seelos Therapeutics' ALS treatment fails mid-stage study

9d ago, source:

Seelos Therapeutics' experimental ALS drug did not meet the main goal of a mid-stage trial, the company said on Tuesday, the ...

Seelos drops as lead drug fails in ALS trial

9d ago, source:

Seelos Therapeutics (SEEL) stock loses ~43% premarket as its ALS drug fails Phase 2/3 trial. Safety concerns raised, but ...

CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why

on MSN ago, source:

Seelos Therapeutics Inc (NASDAQ:SEEL) provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial.  The study was designed to evaluate SLS-005 (IV trehalose), a low molecular weight ...

Optimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Results

8d ago, source:

BTIG analyst Thomas Shrader maintained a Buy rating on Seelos Therapeutics (SEEL – Research Report) yesterday and set a price target of ...

Seelos' IV-administered sugar therapy fails to improve ALS severity in midstage trial

9d ago, source: FierceBiotech

Seelos had hoped to report a sweet victory for its amyotrophic lateral sclerosis treatment, but the IV-delivered sugar failed ...

Seelos Therapeutics files for 3.4M shares secondary offering

on MSN ago, source:

Seelos Therapeutics files for resale of ~3.4M shares, issuable upon exercise of warrants, as required by securities purchase agreement.

Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results

9d ago, source:

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded ...

Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

on MSN ago, source:

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it ...

Rx Rundown: AstraZeneca, Mirador Therapeutics, Orchard Therapeutics and more

6d ago, source: MM&M

Madrigal Pharmaceuticals announced plans to raise $600 million in an offering to support its recently-approved NASH drug ...

Voyager’s tau-reducing therapies show promise in preclinical studies

3h ago, source: alzheimersnewstoday

VY-TAU01, an investigational therapy to prevent tau tangles in Alzheimer’s, was well tolerated and showed promise in ...

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

on MSN ago, source:

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...